ARTICLE | Company News
Centre for the Commercialization of Antibiotics and Biologics and ImmunoBiochem partner for TNBC
September 14, 2018 5:24 PM UTC
The Centre for the Commercialization of Antibodies and Biologics (Toronto, Ontario) provided an undisclosed sum to ImmunoBiochem Corp. (Toronto, Ontario), which the biotech will use to develop IMB-212 which is in development to treat triple-negative breast cancer. ...
BCIQ Company Profiles